New Two-Target drug trial aims to shrink tumors before lung cancer surgery
NCT ID NCT05247684
Summary
This study is testing a new drug called AK112, which targets two cancer pathways at once. It is given to patients before and after surgery for operable non-small cell lung cancer, either alone or combined with standard chemotherapy. The goal is to see if this approach helps shrink tumors before surgery and prevents cancer from coming back afterward.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.